Discussion on "Advanced Vaccine Development Strategies" for Infectious Diseases and Future Pandemics

KDCA and International Vaccine Institute to Hold the 6th Global Vaccine Forum

The Korea Disease Control and Prevention Agency (KDCA) National Institute of Health announced on June 19 that it would co-host the 6th Global Vaccine Forum with the International Vaccine Institute at the Four Seasons Hotel in Jongno-gu, Seoul.

This forum, held under the theme "The Present and Future of mRNA and Vaccine Platform Technologies," provides an opportunity to share the current status of research on advanced vaccine platform technologies and to discuss development strategies in depth with domestic and international experts.

At the forum, Kim Dogeun, Director of the Public Vaccine Development Support Center at KDCA, will present on the status of vaccine development in Korea. Sanjay Singh, CEO of India's Genova Biopharmaceuticals, will deliver a keynote speech on self-amplifying mRNA technology. Dr. Martina Ochs will present CEPI's (Coalition for Epidemic Preparedness Innovations) vaccine development strategy.

Subsequent presentations will include: "Trends in Vaccine Development Using AI" (Baek Minkyoung, Professor at Seoul National University); "Expansion of mRNA Technology Beyond Infectious Disease Prevention and Treatment to Other Diseases Such as Cancer and Genetic Disorders" (Robert Paris, Vice President at Moderna); "Strategic Platforms for Proactive Pandemic Preparedness and Rapid Response" (Hong Kijong, Professor at Gachon University); "Self-amplifying mRNA Technology" (Gerald McInerney, Karolinska Institute); and "Status of Vaccine Development by Korean Companies" (SML Biopharm, GC Biopharma, SK Bioscience). These presentations will shed light on the current state of mRNA technology and discuss strategies for future vaccine development.

Ji Youngmi, Commissioner of the KDCA, emphasized, "Safe and rapid vaccine development is essential to prepare for emerging and re-emerging infectious diseases and future pandemics." She added, "We will continue to share research achievements and strategies on advanced vaccine platform technologies with experts in infectious disease vaccine research, and strengthen global cooperation systems and vaccine development capabilities."